The benefits of reusing EHR data for clinical research studies are numerous. They portend the opportunity to bring new therapies to patients sooner, potentially at a lower cost, and to accelerate learning health cycles-through faster data acquisition in clinical research studies. Metrics have proven that time can be saved, workflow and processes streamlined, and data quality increased significantly. Pilot projects and now actual investigational trials used for regulatory submissions have shown that these benefits support the transformation of clinical research by leveraging EHRs for research. Panelists at a recent collaborative focused on bridging clinical research and clinical care offered varying perspectives on how the latest standards and technologies could be leveraged to facilitate data transfer from EHR systems into clinical research databases, as well as the associated improvements in data quality. Panelists also discussed other avenues to leverage EHR in clinical research. Improvements and exciting possibilities notwithstanding, much work remains. Data ownership and access, attention to metadata and structured data for data sharing, and broader adoption of global standards are key areas for collaboration. With the steady increase in adoption of EHRs around the world, this is an excellent time for all stakeholders to work together and create an environment such that EHRs can be used more readily for research. The capacity for research can thus be increased to provide more highquality information that will contribute to rapid continuous learning health systems from which all patients can benefit.
varied barriers, including but not limited to distrust in the integrity of EHR data and lack of interoperability among EHRs and between research and healthcare systems, have thwarted this value generation while standards, technologies, and processes to enable the use of EHRs for research have been available for almost a decade. 3 Specifically, reuse of data to autopopulate case report forms and research databases is a rare occurrence. 4 Various countries have had differing experiences in this regard, primarily based on their national healthcare systems and electronic health record implementations. 5 The initial primary purpose of EHRs in the United States was to support clinical care, financial billing, and insurance claims. Some EHRs have now begun integrating core workflows for clinical research. Still, sharing of the EHR data for research purposes is challenged by different and inconsistent data standards among organizations using EHRs and EHR vendors, and between clinical care and research entities.
Although an increasing number of countries are adopting certain common healthcare standards and codelists, such as the International Classification of Diseases (ICD) codes, remaining differences between nations, organizations, and languages around healthcare standards have slowed EHR interoperability.
Interest in using EHRs as electronic data source (eSource) for traditional regulated randomized clinical trials has been ongoing for more than two decades. eSource is a research-based term that refers to source data in electronic format and includes the reuse of EHR data and a myriad of other electronic sources of data such as patient reported outcomes, diaries, and wearable devices. Beyond traditional randomized trials, regulators encourage the use of eSource and other data sources for the generation of "real-world evidence" (RWE) based upon real-world data (RWD). Use of RWD may reduce the time needed for data collection and reduce the number of patients required for a study (eg, through the use of "synthetic" standard of care control arms), thereby increasing the speed at which new therapies are delivered to patients. Improved transfer of EHR data to various research databases can provide near real time data to sponsors, allowing more rapid identification of potential safety events and improving access to robust longitudinal patient data for surveillance to assess the safety and efficacy of therapies. Guidance documents from the US Food and Drug Administration (FDA) and communications around the use of eSource and specifically EHRs for research underscore Agency's support. [6] [7] [8] The Learning Health Community (LHC) 9 was formed to mobilize, inspire, and empower multiple and diverse stakeholders nationally and globally to work collaboratively on some of these issues, with a goal to realize person-centered learning health systems anchored in a set of shared consensus, Core Values. The LHC has expressed interest in accelerating the lengthy learning health cycle from healthcare data to research findings that inform clinical decisions-a cycle that has been estimated to take an excessive 17 years and rely on the use of healthcare data for research. Thus far, the LHC has organized two primary initiatives: (1) This collaboration is one of a number of projects supported by the European Commission. I~HD was established with a goal of scaling up "innovations that rely on high quality and interoperable health data." Another relevant EU-funded project was TRANSFoRm, which leveraged EHRs to populate case report forms for a study on gastroesophageal reflux disease. 19 In addition to using RFD for this purpose, they also developed a BRIDG-based ontology and a patient-reported outcomes tool that extended the CDISC Operational Data Model (ODM) to function on mobile hand-held devices. The ODM extension is now publicly available through CDISC.
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In Japan, a common storage standard for EHR data (SS-MIX) was leveraged to populate eCRFs for research. 21 The CDISC ODM standard for data archiving and exchange was implemented by the University of Osaka and also in Europe to transport data from EHRs for research data collection purposes. 22, 23 In summary, data standards for regulated research have been increasingly harmonized and adopted globally, through efforts by model. 27 It is now a research-healthcare standard through the International Standards Organization (ISO), 28 CDISC, and HL7 with a broad scope of protocol-driven research, including genomics. Nevertheless, additional collaborative efforts are needed to harmonize standards around the world for both healthcare and research.
| New impetus: Late 2000s to present
On the basis of this global progress, it appears that technical capabilities and global research standards to conduct a regulated research study While the lack of global harmonization and adoption of data standards is an impediment that forms the basis for others such as the lack of interoperability, data integration, efficiency, and processes redesign, it is not the only impediment faced in this desire to bridge research and healthcare. Others include aspects of data privacy, legal agreements, increasing complexity of research requirements, costs associated with data access and integration, and related issues.
| Panelists
The Panelists consisted of seven participants from various types of organizations: NIH Clinical Center, Duke University, monARC,
research before addressing specific aspects of leveraging EHRs.
As depicted in Figure 1 , the panel was composed of a reasonable representation of the stakeholders interested in the reuse of EHR data for clinical research; however, it was not inclusive of all stakeholders'
perspectives. Historically, one of the main challenges to finding a solution for eSource and the use of EHRs for research has been that only a subset of the relevant stakeholders' perspectives was included. The panelists had varied backgrounds and represented perspectives outside of their current organization.
| Data transfer from EHRs to research databases
A recent study conducted by the Tufts Center for the Study of Drug
Development assessed the evolving eClinical Landscape. 41 Out of 257 unique global companies, it was found that all are using electronic data capture; however, there are still over 30% of research studies where data are collected on paper case report forms. Although 50% of the companies anticipate having a strategy for using EHRs by 2020, only 20% are employing them currently. Reentry of data from source medical records is still the norm, and the time from patient visit to reentry of data for research has increased from an average of 6.9 days to 8.1 days over the past decade. Reentry of data not only lengthens the access time but also negatively impacts data quality, as evidenced by the Nordo study (see below).
The Tufts study also indicates that global drug development programs are becoming increasingly complex, the number and breadth of data points collected for each protocol is increasing and the number and variety technology applications employed is growing. Interestingly, this does not appear to be improving efficiency. In fact, the opposite was observed; cycle times such as time to lock a database at the end of a study have lengthened during the past decade. Continuation of FIGURE 1 List of stakeholders (blue represents panelists) concerned with or affected by issues around the use of EHR data for clinical research. 40 (blue represents organizations most related to those who participated in the panel discussions) these trends not only increases the time and cost of developing therapies and burden on sites, but also impedes data sharing efforts.
Fortunately, data transfer from EHRs directly into research databases offers multiple benefits. Two panelists offered direct experience of implementing such solutions.
| Streamlining clinical research process
Amy Nordo, who worked for Duke University and recently joined
Pfizer, elaborated on the recent eSource study she conducted at Duke University. 2 This pilot was designed to compare eSource-enabled data collection and the traditional manual transcription of data into eCRF based on the RFD standard Table 1 can be transferred versus manually transcribing and verifying data.
The application is used in production on a major leukemia program, the Beat AML Master Trial. 43 Clinical Pipe's use in a production on a trial is an encouragement that the many factors impacting the reuse 
| Reduced resource requirements and improved data quality
The Duke University Comparative Effectiveness Study autopopulated 1.75% of the eCRF data collected, resulting in statistically significant improved data quality and saved time. Times to complete the forms and data quality were assessed. The results indicated that time was reduced by 37% (from 213 s to 133 s) when eSource process was implemented to collect demographic data (Table 1) , and the quality of data improved from a 9% error rate to a 0% error rate when eSource was implemented. Scaling these findings to 60% of the eCRF data being autopopulated would yield an impressive improvement in data collection time and data quality, both of which would positively impact the time necessary to conduct clinical research studies and potentially allow the therapies to come to market faster. Another potential downstream effect of decreased time lapse in data availability to the sponsor 44 is the earlier detection of adverse events, thereby allowing faster response from the sponsor leading to improved patient safety. Additional research is necessary to prove potential downstream effects.
| OTHER APPLICATIONS OF EHRS FOR RESEARCH

| Real world data
While the above example implementations offered examples pertaining to observational research and investigational trials, Act, 45 to increase the use of RWE based upon RWD. The challenges with RWD, however, remain the reliability of the data sources, the quality of the data, the cost, linkage and integration across sources, data consistency through application of appropriate standards, and unclear regulatory guidelines. Several panelists offered examples of their work and interest in this developing field of research.
| Views on empowering patients by Komathi Stem
Komathi Stem discussed the need for a paradigm shift in the healthcare ecosystem from prioritizing data ownership to data access. should also be simplified and case report forms should be consistent; creating "works of art" and one-off requirements for data to be collected in each study are a burden and a barrier to streamlining research.
| DISCUSSION
Integration challenges include both technical and semantic reasons, and semantic issues have been ascribed to the tendency to overestimate the reliability of the data being exchanged. 51 Challenges in terms of the standards must address harmonization of semantics and will require consensus-building around the use of FHIR resources that support healthcare and research entities if these are to be useful and adopted for research, especially global regulated research. In a blog entitled "Be careful how you fan the FHIRs of interoperability," it is cautioned that lessons can be learned from clinical imaging standards development, wherein defined clinical protocols and data exchange specifications alone were not sufficient for true interoperability. 52 Common nomenclatures, definitions, and other metadata were also required for data and images to be reliably and meaningfully shared.
Beyond lessons from the domain of clinical imaging, it would also be prudent to learn from the research arena, which has a wealth of experience in the area of provenance, audit trails, traceability, and retaining data integrity used for regulatory purposes.
On the health care side of the ledger, EHRs must substantially increase the ability to manage metadata and allow for creating data sets based less on individual patients and more on their metadata The value propositions extend to the opportunity to bring new therapies to patients sooner, potentially at a lower cost, and learning more rapidly from healthcare information-thereby accelerating learning health cycles.
Unfortunately, while the benefits are numerous, remaining impediments are multi-faceted and will require collaboration among numerous stakeholders. Broad adoption and harmonization of global standards, along with processes and tools from the recent example of data transfer from EHRs to research databases, will be a starting point to offer new opportunities to overcome the remaining barriers.
With the steady increase in adoption of EHRs around the world, this is an excellent time for all clinicians, researchers, and other stakeholders to collaborate. Together, these groups can change the environment such that EHRs can be used more readily for research and the capacity for research can be increased to provide high quality information that will contribute to rapid, continuous learning health systems from which all patients can benefit.
